2025-07-24 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data. The report is structured with numerical data first, followed by analysis, and presented in English.

## Merck & Co Inc (MRK) Analysis Report

**Ticker:** MRK
**Company Name:** Merck & Co Inc
**Description:** A global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -4.397%
*   **VOO Cumulative Return:** 97.075%
*   **Absolute Deviation:** -101.472%
*   **Deviation Range:** Max: 23.1, Min: -102.3
*   **Relative Deviation:** 0.6

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO) over the period analyzed. The current cumulative return difference is -101.5%. The relative deviation of 0.6 indicates that the underperformance is near the extreme lower end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha    | Beta  | Cap(B) |
|------------|---------|---------|----------|-------|--------|
| 2015-2017  | 5.0%    | 58.2%   | -24.0%   | -0.0  | 138.9  |
| 2016-2018  | 43.0%   | 66.4%   | 25.0%    | -0.1  | 188.6  |
| 2017-2019  | 40.0%   | 66.4%   | 11.0%    | 0.3   | 224.5  |
| 2018-2020  | 20.0%   | 66.4%   | 0.0%     | 0.3   | 201.9  |
| 2019-2021  | -1.0%   | 65.6%   | -50.0%   | 0.3   | 198.3  |
| 2020-2022  | 13.0%   | 69.5%   | 11.0%    | 0.3   | 287.0  |
| 2021-2023  | 31.0%   | 69.5%   | 13.0%    | 0.3   | 282.0  |
| 2022-2024  | -7.0%   | 69.5%   | -33.0%   | 0.2   | 257.4  |
| 2023-2025  | -56.0%  | 68.9%   | -105.0%  | 0.5   | 211.1  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows fluctuating performance with significant drops in recent periods (2022-2025).
*   **MDD:** Consistently high Maximum Drawdown values indicate significant risk.
*   **Alpha:** Mostly negative alpha values suggest underperformance relative to the benchmark, particularly pronounced in recent years.
*   **Beta:** Generally low beta values suggest lower sensitivity to market movements.
*   **Capitalization:** Company size has fluctuated.

### 2. Recent Stock Price Action

*   **Last Price:** 81.61
*   **Last Market Data:**
    *   Price: 84.09
    *   Previous Close: 81.61
    *   Change: 3.04
*   **5-Day Moving Average:** 80.966
*   **20-Day Moving Average:** 81.403
*   **60-Day Moving Average:** 79.858

**Analysis:** The recent market data shows a significant price increase (change of 3.04), suggesting a recent positive price movement. The price is above the 5-day and 20-day moving averages, but near the 60-day moving average, suggesting a possible short-term upward trend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3359 (Low Risk)
*   **RSI:** 49.329
*   **PPO:** -0.366
*   **Hybrid Signal:** cash_69%_Sell 0.6% of holdings (3 shares - Caution - MRI:0.34)
*   **Recent (20-Day) Relative Deviation Change:** -1.3 (Negative - Short-term decline)
*   **Expected Return (%):** -1129.2

**Analysis:**

*   The **MRI** indicates low market risk.
*   The **RSI** of 49.329 suggests neutral momentum (neither overbought nor oversold).
*   The **PPO** is slightly negative, indicating a possible short-term downward trend.
*   The **Hybrid Signal** suggests a cautious stance, recommending holding a significant cash position and selling a small portion of holdings.
*   The negative change in the 20-day relative deviation indicates a recent short-term decline.
*   The **Expected Return** is extremely negative, suggesting significant underperformance relative to the S&P 500 in the long term.
*   The recent market data shows a significant price increase (change of 3.04), which could indicate a sharp rebound or reaction to recent news, earnings, or events.

### 4. Recent News & Significant Events

*   **[2025-07-23]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-21]:** Analysts discussing recent performance and outlook.
*   **[2025-07-24]:** Notable stock volatility.
*   **[2025-07-22]:** Market experts highlighting both risks and opportunities.

**Analysis:** Recent news indicates a period of change, volatility, and scrutiny. Analysts are actively discussing the company's outlook, and market experts advise monitoring news and announcements.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-05-02 | 2.01  | 15.53 B$    |
| 2024-11-06 | 1.25  | 16.66 B$    |
| 2024-08-05 | 2.15  | 16.11 B$    |
| 2024-05-03 | 1.88  | 15.78 B$    |
| 2025-05-02 | 1.88  | 15.78 B$    |

**Analysis:** The data shows fluctuating EPS and revenue. The most recent data has a lower revenue and similar EPS compared to previous quarters.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-03-31 | $15.53B    | 77.98%        |
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE      |
|------------|------------|----------|
| 2025-03-31 | $48.34B    | 10.51%   |
| 2024-12-31 | $46.31B    | 8.08%    |
| 2024-09-30 | $44.50B    | 7.09%    |
| 2024-06-30 | $43.58B    | 12.52%   |
| 2024-03-31 | $40.36B    | 11.80%   |

**Analysis:**

*   **Revenue:** Revenue has fluctuated, with the most recent quarter showing a decrease.
*   **Profit Margin:** Profit margins are consistently high, indicating strong profitability.
*   **Equity:** Equity has been increasing steadily, reflecting growth in the company's net assets.
*   **ROE:** ROE has fluctuated, indicating varying levels of return on equity.

### 7. Overall Analysis

Merck & Co Inc (MRK) has significantly underperformed the S&P 500, with negative cumulative returns and a very negative expected return. While the company exhibits strong profit margins and a low market risk indicator, recent data shows fluctuating earnings, revenues and negative alpha values.

Technical indicators suggest a mixed outlook, with a recent price increase but a cautious hybrid signal. Recent news points to a period of volatility and significant developments. Investors should closely monitor these developments and consider the company's long-term underperformance and financial data trends before making investment decisions. The data suggests a cautious approach is warranted at this time.
